FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants

Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact sheet.

Read the full article here

Related Articles